Yarrow Bioscience Inc., a biotechnology company based in New Haven, recently raised approximately $200 million following its reverse merger with VYNE Therapeutics Inc., completing the transaction in late July and beginning its trading on the Nasdaq under the ticker YARW. The company focuses on developing treatments for autoimmune thyroid diseases and has launched mid-stage clinical trials for its lead drug candidate, YB-101, which has received Fast Track designation from the FDA. Yarrow’s funding, primarily from RTW Investments and other investors, is projected to sustain its operations through 2028.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://hartfordbusiness.com/article/new-haven-biotech-goes-public-after-merger-raises-200m/
